Loading
A phase 1/2 trial of EP0031 and Pemetrexed in non-small-cell lung cancer, run by Ellipses Pharma, now recruiting.
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies is a phase 1/2 interventional study registered as NCT05443126 by Ellipses Pharma, with 265 participants planned, started 2022-09-30 and due to reach its primary completion in 2027-03. Interventions recorded: EP0031, Platinum chemotherapy and Pemetrexed.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ellipses Pharma and the tag pipeline.
Shares Ellipses Pharma and the tag pipeline.
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/